Constellation Pharmaceuticals to Participate in Investor Conference

Rhea-AI Summary

Constellation Pharmaceuticals (Nasdaq: CNST) announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 8:00 AM EDT. CEO Jigar Raythatha will present, and a live audio webcast will be available on the company’s Investor Relations website. The presentation will be archived for 30 days post-event. Constellation focuses on developing novel therapeutics that target gene expression to treat serious medical needs in cancer patients, including its BET inhibitor CPI-0610 and EZH2 inhibitors CPI-1205 and CPI-0209.

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference.  Jigar Raythatha, CEO, will present at the Goldman Sachs 41st Annual Global Healthcare Conference at 8:00 AM EDT on June 11.  A live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  The audio webcast replay will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers.  The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. 

Contacts

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com 

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com 

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com 

Source: Constellation Pharmaceuticals

FAQ

When will Constellation Pharmaceuticals present at the Goldman Sachs healthcare conference?

Constellation Pharmaceuticals will present on June 11, 2020, at 8:00 AM EDT.

Where can I find the audio webcast of Constellation Pharmaceuticals' presentation?

The audio webcast will be available on Constellation Pharmaceuticals' Investor Relations website.

What is the focus of Constellation Pharmaceuticals' research?

Constellation Pharmaceuticals focuses on developing therapeutics that modulate gene expression to treat cancer.

What are the names of Constellation Pharmaceuticals' key therapeutics?

Key therapeutics include BET inhibitor CPI-0610 and EZH2 inhibitors CPI-1205 and CPI-0209.

How long will the audio replay of the presentation be available?

The audio replay will be available for 30 days after the live presentation.